Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02300558 · ClinicalTrials.gov registry record · Phase 3
Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT02300558 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 41 participants.
The verdict
NCT02300558, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3. During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or eleclazine placebo. Following the single-blind treatment period, participants who have not permanently discontinued study drug will be eligible, at the discretion of the investigator, to continue receiving eleclazine during an open-label extension (OLE) phase.
Interventions
- DRUG Eleclazine
- DRUG Eleclazine placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2017-02-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02300558
The ClinicalTrials.gov registry entry for NCT02300558 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Eleclazine is the first listed.
NCT02300558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02300558 about?
NCT02300558 is a clinical study titled "Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3". The primary objective of this study is to evaluate the effect of oral eleclazine on mean daytime QTcF interval after 24 weeks of treatment with elecalzine in participants with long QT syndrome Type 3. During the single-blind treatment period (24 weeks), participants will receive eleclazine and/or el...
What is the current status of trial NCT02300558?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2014-12-17. Estimated completion is 2017-02-15.
What interventions are being tested in trial NCT02300558?
The interventions under investigation include: Eleclazine (DRUG), Eleclazine placebo (DRUG).
Who is sponsoring clinical trial NCT02300558?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.